Comment on double-strand break repair and rapamycin treatment.
Pajonk
F
F
McBride
W H
WH
D001260:Ataxia Telangiectasia / Q000378:metabolism; D053148:Caspase 3; D020169:Caspases / Q000378:metabolism; D002453:Cell Cycle / Q000187:drug effects / Q000528:radiation effects; D016572:Cyclosporine / Q000494:pharmacology; D004260:DNA Repair; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005347:Fibroblasts / Q000187:drug effects / Q000528:radiation effects; D017320:HIV Protease Inhibitors / Q000494:pharmacology; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects / Q000528:radiation effects; D010447:Peptide Hydrolases / Q000378:metabolism; D046988:Proteasome Endopeptidase Complex; D011494:Protein Kinases / Q000378:metabolism; D019893:Ribosomal Protein S6 Kinases; D019438:Ritonavir / Q000494:pharmacology; D015398:Signal Transduction / Q000187:drug effects / Q000528:radiation effects; D020123:Sirolimus / Q000494:pharmacology*
D004791:Enzyme Inhibitors; D017320:HIV Protease Inhibitors; D016572:Cyclosporine; D011494:Protein Kinases; D019893:Ribosomal Protein S6 Kinases; D010447:Peptide Hydrolases; C505407:CASP3 protein, human; D053148:Caspase 3; D020169:Caspases; D046988:Proteasome Endopeptidase Complex; C061553:ATP dependent 26S protease; D019438:Ritonavir; D020123:Sirolimus